- Home
- PRHIZ vs PBYI Comparison
PRHIZ vs PBYI Comparison
Compare PRHIZ & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRHIZ
- PBYI
- Stock Information
- Founded
- PRHIZ N/A
- PBYI 2010
- Country
- PRHIZ United States
- PBYI United States
- Employees
- PRHIZ N/A
- PBYI 172
- Industry
- PRHIZ Property-Casualty Insurers
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- PRHIZ Finance
- PBYI Health Care
- Exchange
- PRHIZ Nasdaq
- PBYI Nasdaq
- Market Cap
- PRHIZ 220.0M
- PBYI 263.4M
- IPO Year
- PRHIZ N/A
- PBYI N/A
- Fundamental
- Price
- PRHIZ $20.40
- PBYI $5.35
- Analyst Decision
- PRHIZ
- PBYI Strong Buy
- Analyst Count
- PRHIZ 0
- PBYI 1
- Target Price
- PRHIZ N/A
- PBYI $7.00
- AVG Volume (30 Days)
- PRHIZ N/A
- PBYI 468.3K
- Earning Date
- PRHIZ N/A
- PBYI 11-06-2025
- Dividend Yield
- PRHIZ N/A
- PBYI N/A
- EPS Growth
- PRHIZ N/A
- PBYI 434.29
- EPS
- PRHIZ N/A
- PBYI 0.97
- Revenue
- PRHIZ N/A
- PBYI $238,062,000.00
- Revenue This Year
- PRHIZ N/A
- PBYI N/A
- Revenue Next Year
- PRHIZ N/A
- PBYI N/A
- P/E Ratio
- PRHIZ N/A
- PBYI $5.38
- Revenue Growth
- PRHIZ N/A
- PBYI 8.63
- 52 Week Low
- PRHIZ N/A
- PBYI $2.32
- 52 Week High
- PRHIZ N/A
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- PRHIZ N/A
- PBYI 58.40
- Support Level
- PRHIZ N/A
- PBYI $5.00
- Resistance Level
- PRHIZ N/A
- PBYI $5.59
- Average True Range (ATR)
- PRHIZ 0.00
- PBYI 0.26
- MACD
- PRHIZ 0.00
- PBYI -0.02
- Stochastic Oscillator
- PRHIZ 0.00
- PBYI 46.67
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.